First Cancer Patients in Korea Treated with Varian HyperArc High-Definition Radiotherapy

PALO ALTO, Calif., May 16, 2018 /PRNewswire/ -- Varian (NYSE: VAR) announced two patients with brain cancer were the first patients in Korea to be treated using the company's HyperArc^™ High Definition Radiotherapy (HDRT), a new type of radiosurgery treatment, at the Ajou University Hospital. HyperArc is designed to automate and simplify sophisticated treatments such as stereotactic radiosurgery (SRS) and make them available to more cancer patients around the world.

"We have been utilizing Varian's cancer treatment technology for over 20 years with great success," said Dr. Young-Taek Oh, chief oncologist, Ajou University Hospital. "HyperArc treatments are a big step forward for both clinicians and patients, and we look forward to quickly expanding the use of these treatments at our clinic."

"We are excited that HyperArc treatments have begun in Korea," said Kenneth Tan, managing director South East Asia & Korea of Varian's Oncology Systems business. "By partnering with leading institutions like Ajou University Hospital to deliver advanced cancer treatments to more patients, we are taking another important step in achieving our vision of a world without fear of cancer."

HyperArc capitalizes on the unique capabilities of Varian's TrueBeam^™ and EDGE^™ treatment systems. HyperArc treatments allow clinicians the ability to deliver more compact radiation doses that closely conform to the size, shape, and location of tumors while sparing more surrounding healthy tissue. These advanced treatments can be delivered in a conventional treatment time slot. The treatment planning for HyperArc is supported by Varian's Eclipse^™ treatment planning software.

For more information on HyperArc, visit www.varian.com/hyperarc

About Varian
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630
[email protected]

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163
[email protected]

SOURCE Varian

Related Links

http://www.varian.com